Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical
资讯
2024-09-19
Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research ...